National Cancer Institute National Cancer Institute
U.S. National Institutes of Health National Cancer Institute
NCI Home Cancer Topics Clinical Trials Cancer Statistics Research & Funding News About NCI

Understanding Cancer Series: Genetic Variation (SNPs)
< Back to Main
    Posted: 01/28/2005    Reviewed: 09/01/2006
Page Options
Print This Page  Print This Page
Print This Document  Print This Document
View Entire Document  View Entire Document
E-Mail This Document  E-Mail This Document
PDF Version  View/Print PDF
PowerPoint Version  View/Print PowerPoint
Quick Links
Director's Corner

Dictionary of Cancer Terms

NCI Drug Dictionary

Funding Opportunities

NCI Publications

Advisory Boards and Groups

Science Serving People

Español
NCI Highlights
Virtual and Standard Colonoscopy Both Accurate

New Study of Targeted Therapies for Breast Cancer

The Nation's Investment in Cancer Research FY 2009

Cancer Trends Progress Report: 2007 Update

Past Highlights
You CAN Quit Smoking Now!
Slide 31 : Arylamines and Bladder Cancer previousnext

Some workers in the dye industry, after occupational exposure to arylamines, develop an increased risk of bladder cancer. Scientists suspect that SNPs may be involved.

In the liver, arylamines can have two fates, because there are two enzymes available to act on them.

An acetylator enzyme can deactivate arylamines, converting them into nonreactive compounds that are safely removed from the body.

Or arylamines can be activated by a deaminator enzyme in the liver to become precarcinogens that are carried to the bladder. There they are converted into carcinogens.

Arylamines and Bladder Cancer

< Previous  |  Index  |  Next Slide >


A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov